Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients
Author:
Hafez Gaye1ORCID, Malyszko Jolanta2, Golenia Aleksandra3, Klimkowicz-Mrowiec Aleksandra4, Ferreira Ana Carina56ORCID, Arıcı Mustafa7, Bruchfeld Annette89ORCID, Nitsch Dorothea10, Massy Ziad A1112ORCID, Pépin Marion1213ORCID, Capasso Giovambattista1415ORCID, Mani Laila-Yasmin16ORCID, Liabeuf Sophie1718ORCID, Capasso Giovambattista, Andrade Alexandre, Bachmann Maie, Bumblyte Inga, Covic Adrian Constantin, Delgado Pilar, Endlich Nicole, Engvig Andreas, Fouque Denis, Franssen Casper, Frische Sebastian, Garneata Liliana, Gesualdo Loreto, Giannakou Konstantinos, Goumenos Dimitrios, Kartal Ayşe Tuğba, Liabeuf Sophie, Mani Laila-Yasmin, Marti Hans-Peter, Mayer Christopher, Nielsen Rikke, Pešić Vesna, Rroji (Molla) Merita, Sakkas Giorgos, Spasovski Goce, Stevens Kate, Vazelov Evgueniy, Viggiano Davide, Zacharia Lefteris, Ferreira Ana Carina, Malyszko Jolanta, Hoorn Ewout, Figurek Andreja, Unwin Robert, Wagner Carsten, Wanner Christoph, Bruchfeld Annette, Pepin MarionORCID, Wiecek Andrzej, Nitsch Dorothea, Fridolin Ivo, Hafez Gaye, Romeo Maria José Soler, Barbieri Michelangela, Batinić Bojan, Carrasco Laura, Carriazo Sol, Gansevoort Ron, Martino Gianvito, Raso Francesco Mattace, Nistor Ionut, Ortiz Alberto, Paolisso Giuseppe, Rastenytė Daiva, Stefan Gabriel, Tedeschi Gioacchino, Massy Ziad, Bikbov Boris, Endlich Karl Hans, Godefroy Olivier, Kossioni Anastassia, Kurganaite Justina, Perico Norberto, Remuzzi Giuseppe, Grodzicki Tomasz, Trepiccione Francesco, Zoccali Carmine, Arici Mustafa, Blankestijn Peter, Eckardt Kai-Uwe, Fliser Danilo, Jiménez Eugenio Gutiérrez, Konig Maximilian, Rychlik Ivan, Deleidi Michela, Reusz George, Farisco Michele, Perico Norberto, Silva Pedro Imenez, Bobot Mickaël, Golenia Aleksandra, Perna Alessandra, Idrizi Alma, Hansen Brian, Simeoni Mariadelina,
Affiliation:
1. Department of Pharmacology, Faculty of Pharmacy, Altinbas University , Istanbul , Turkey 2. Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw , Warsaw , Poland 3. Department of Neurology, Medical University of Warsaw , Warsaw , Poland 4. Department of Internal Medicine and Gerontology, Jagiellonian University Medical College , Cracow , Poland 5. Nephrology Department, Centro Hospitalar e Universitário de Lisboa Central , Lisbon , Portugal 6. Universidade Nova de Lisboa-Faculdade de Ciências Médicas-Nephology , Lisbon , Portugal 7. Department of Internal Medicine, Division of Nephrology, Faculty of Medicine, Hacettepe University , Ankara , Turkey 8. Department of Health, Medicine and Caring Sciences, Linköping University , Linköping , Sweden 9. Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet , Stockholm , Sweden 10. Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine , London , UK 11. Paris-Saclay University, UVSQ, Inserm, Clinical Epidemiology Team , Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Villejuif , France 12. Department of Nephrology, Ambroise Paré University Medical Center, APHP , Paris , France 13. Department of Geriatrics, Ambroise Paré University Medical Center, APHP , Boulogne-Billancourt , France 14. Department of Translational Medical Sciences, University of Campania Luigi Vanvitelli , Naples , Italy 15. Biogem Research Institute , Ariano Irpino , Italy 16. Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland 17. Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens University Medical Center , Amiens , France 18. MP3CV Laboratory, EA7517, Jules Verne University of Picardie , Amiens , France
Abstract
ABSTRACT
There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.
Publisher
Oxford University Press (OUP)
Subject
Transplantation,Nephrology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|